Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolgolimab plus platinum chemotherapy ± bevacizumab vs placebo in recurrent or metastatic cervical cancer
CTR20210924Phase 3Terminated
- Sponsor
- Shangyao Bokang Biopharmaceutical
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of prolgolimab in Cervical Cancer (CC), sponsored by Shangyao Bokang Biopharmaceutical. Started May 2021; status: terminated.
02
Drugs
prolgolimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20210924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210924.